- Home
- SXC vs PLRX Comparison
SXC vs PLRX Comparison
Compare SXC & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXC
- PLRX
- Stock Information
- Founded
- SXC 1960
- PLRX 2015
- Country
- SXC United States
- PLRX United States
- Employees
- SXC N/A
- PLRX N/A
- Industry
- SXC Steel/Iron Ore
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- SXC Industrials
- PLRX Health Care
- Exchange
- SXC Nasdaq
- PLRX Nasdaq
- Market Cap
- SXC 722.8M
- PLRX 641.5M
- IPO Year
- SXC N/A
- PLRX 2020
- Fundamental
- Price
- SXC $12.63
- PLRX $12.85
- Analyst Decision
- SXC Strong Buy
- PLRX Strong Buy
- Analyst Count
- SXC 1
- PLRX 7
- Target Price
- SXC $13.00
- PLRX $40.50
- AVG Volume (30 Days)
- SXC 907.2K
- PLRX 474.0K
- Earning Date
- SXC 10-31-2024
- PLRX 11-07-2024
- Dividend Yield
- SXC 3.77%
- PLRX N/A
- EPS Growth
- SXC 55.48
- PLRX N/A
- EPS
- SXC 1.01
- PLRX N/A
- Revenue
- SXC $1,970,000,000.00
- PLRX N/A
- Revenue This Year
- SXC N/A
- PLRX N/A
- Revenue Next Year
- SXC N/A
- PLRX $585.71
- P/E Ratio
- SXC $12.42
- PLRX N/A
- Revenue Growth
- SXC N/A
- PLRX N/A
- 52 Week Low
- SXC $7.47
- PLRX $10.22
- 52 Week High
- SXC $12.81
- PLRX $19.62
- Technical
- Relative Strength Index (RSI)
- SXC 78.64
- PLRX 42.81
- Support Level
- SXC $12.29
- PLRX $12.01
- Resistance Level
- SXC $12.71
- PLRX $12.94
- Average True Range (ATR)
- SXC 0.42
- PLRX 0.91
- MACD
- SXC 0.03
- PLRX -0.28
- Stochastic Oscillator
- SXC 93.75
- PLRX 25.12
About SXC SunCoke Energy Inc.
SunCoke Energy Inc operates as an independent producer of coke in the Americas. The company operates through three segments: Domestic Coke, Brazil Coke, and Logistics. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal producing, and other manufacturing-based customers.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.